Oral Vancomycin for Preventing Clostridium Difficile Recurrence

• Status: Terminated
• Trial end date: 2021-04-22
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rochester General Hospital
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Age 18 years and older

• Any history of Clostridium difficile infection based on a positive Clostridium difficile stool test performed at a lab affiliated with Rochester Regional Health System or patient report

• A new in-patient admission, with an antibiotic treatment plan for greater than 48 hours

Exclusion Criteria:

• Documented allergy and/or adverse drug reaction to vancomycin

• Pregnant

• Patients who are admitted with a current episode of Clostridium difficile infection

• Patients with total colectomy